Entrectinib(Rozlytrek)

Entrectinib is a prescription drug approved by the U.S. FDA in August 2019. It targets TRKA/B/C (encoded by the NTRK1/2/3 genes), ROS1, and ALK. Use of this medication must be under the guidance of a physician.

Targets

TRKA, TRKB, TRKC (encoded by NTRK1, NTRK2, NTRK3 genes); ROS1 (ROS proto-oncogene 1); ALK (anaplastic lymphoma kinase).

Dosage and Administration

Route and frequency of entrectinib administration: Orally at 600 mg once daily.

The dosage of entrectinib should be adjusted according to the patient’s actual condition. For specific adjustments, consult a doctor and strictly follow medical advice.

Recommended reading: Dosage and Administration of Entrectinib

Adverse Reactions

Common adverse reactions: Increased risk of infection, fever, etc.

Serious adverse reactions: Heart failure, central nervous system effects, etc.

Reference article: Adverse Reactions of Entrectinib

Use in Special Populations

Pregnancy: This treatment may cause harm to the fetus developing in utero. Pregnancy or causing someone else to become pregnant is strictly prohibited during treatment. Before starting treatment, consult a doctor or nurse about effective contraceptive methods. Females must not become pregnant for at least 5 weeks after treatment ends. Males must not cause someone else to become pregnant for at least 3 months after treatment ends.

Lactation: It is not known whether this drug is excreted in human milk. Physicians generally advise against breastfeeding during treatment and for 3 days after the last dose.

Precautions

1. Patients are advised to swallow entrectinib capsules whole. Do not chew or crush the capsules.

2. If a dose is missed, take it as soon as remembered unless it is less than 12 hours before the next scheduled dose.If vomiting occurs immediately after dosing, an additional dose should be taken to replace the vomited dose.

3. There is a risk of heart failure. It must be emphasized: if new or worsening signs or symptoms of heart failure (e.g., dyspnea, edema) occur, inform a healthcare professional immediately.

from FDA，2024.01